SUITE F200

RADNOR

(Street)

(City)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

10% Owner

Chief Medical Officer

Form filed by More than One Reporting Person

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Other (specify below)

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

150 N. RADNOR CHESTER ROAD.

PA

(State)

Check this box to indicate that a transaction was made pursuant to a

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	purchase or sale of er issuer that is intended affirmative defense or 10b5-1(c). See Instru	quity securities of the d to satisfy the conditions of Rule					
- 1	1. Name and Address of Rodman David			2. Issuer Name and Ticker or Trading Symbol Mineralys Therapeutics, Inc. [MLYS]	5. Relat (Check	son(s) to Issuer	
	(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/12/2024	X	Director Officer (give title below)	Other (below)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

4. If Amendment, Date of Original Filed (Month/Day/Year)

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	02/12/2024		M		5,017	A	\$0.54	37,917	D	
Common Stock	02/12/2024		M		6,349	A	\$1.08	44,266	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		6. Date Exerc Expiration D (Month/Day/	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$ 0.54 ⁽¹⁾	02/12/2024		M			5,017	(2)	03/11/2031	Common Stock	5,017	\$0	55,190	D	
Stock Option	\$1.08 ⁽³⁾	02/12/2024		M			6,349	(4)	07/11/2031	Common Stock	6,349	\$0	215,851	D	

Explanation of Responses:

- 1. Due to a rounding error, the exercise price for this stock option was originally reported as \$0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
- 2. The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
- 3. Due to a rounding error, the exercise price for this stock option was originally reported as \$1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
- 4. The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

Remarks:

/s/ Adam Levy, Attorney-in-fact 02/13/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

19087

(Zip)

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.